Status:
UNKNOWN
Biomarkers in Pediatric Congenital Heart Disease and PAH
Lead Sponsor:
University Medical Center Groningen
Conditions:
Congenital Heart Disease
Pulmonary Arterial Hypertension
Eligibility:
All Genders
1-18 years
Brief Summary
Nowadays, biomarkers are broadly used in clinical practice. Blood-derived biomarkers fulfil an important role in the field of cardiology. However, most biomarkers have been investigated for adult left...
Detailed Description
OBJECTIVES: Primary Objective: The primary objective is to investigate cross-sectionally (at baseline and after one year) the association between various emerging blood-derived biomarkers and right ...
Eligibility Criteria
Inclusion
- Age 0-18 years
- Patients with Pulmonary Arterial hypertension: diagnosis confirmed according to the standards of the National Expertise Center for PH in childhood.
- Patients with CHD with an abnormally loaded right ventricle including tetralogy of Fallot (TOF), pulmonary (valve) stenosis (PS), pulmonary insufficiency (PI), atrial septal defect (ASD), ventricular septal defect (VSD) and total anomalous pulmonary venous return (TAPVR): diagnosis confirmed by echocardiography or cardiac MRI in UMCG-CCH.
Exclusion
- Age \>18 years
- Not familiar with Dutch language
- Pregnant
- Concomitant musculoskeletal disease
- No echocardiography available within three months before or after blood collection
- Being under examination for non-diagnosed disease at time of investigation
Key Trial Info
Start Date :
December 5 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2024
Estimated Enrollment :
380 Patients enrolled
Trial Details
Trial ID
NCT04130243
Start Date
December 5 2017
End Date
December 1 2024
Last Update
October 18 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Medical Center Groningen
Groningen, Netherlands, 9713GZ